Abstract
The design of novel therapeutic strategies based on tumour molecular features and specific carcinogenetic pathways is a compelling issue. Tumours arising in BRCA1-defective individual carriers constitute a specific entity which resembles the basal-like molecular phenotype for breast tumours, while BRCA1-defective ovarian cancer has a molecular signature which is also shared by a substantial amount of sporadic tumours. Several important issues are derived from the role of BRCA1 gene product in critical cell functions like DNA repair, transcription regulation and cell cycle checkpoint control. It has been recently demonstrated that the loss of such functions in BRCA1-defective tumours results in a specific profile of sensitivity to anti-cancer drugs. Moreover, BRCA1 appears to retain a critical role in the response of cells to stress as well as to the growth promoting stimuli generated by estrogens and peptide growth factors. Therefore, it is conceivable that loss of a functional BRCA1 produces a general de-arrangement of cellular signaling which might allow the identification of specific and high priority targets and lead to individualized signal transduction-based anti-tumour approaches. We will review the most important findings related to BRCA1 effects on cellular signaling in order to depict a general scenario for selective chemopreventive and therapeutic strategies.
Keywords: Hereditary cancer, breast cancer, ovarian cancer, BRCA1, signal trasduction, prevention, targeted therapy
Current Signal Transduction Therapy
Title: Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours
Volume: 2 Issue: 2
Author(s): P. Tagliaferri, P. Tassone, A. Pietragalla, M. S. Rotundo, V. Barbieri, A. Budillon, M. Caraglia, F. S. Costanzo and S. Venuta
Affiliation:
Keywords: Hereditary cancer, breast cancer, ovarian cancer, BRCA1, signal trasduction, prevention, targeted therapy
Abstract: The design of novel therapeutic strategies based on tumour molecular features and specific carcinogenetic pathways is a compelling issue. Tumours arising in BRCA1-defective individual carriers constitute a specific entity which resembles the basal-like molecular phenotype for breast tumours, while BRCA1-defective ovarian cancer has a molecular signature which is also shared by a substantial amount of sporadic tumours. Several important issues are derived from the role of BRCA1 gene product in critical cell functions like DNA repair, transcription regulation and cell cycle checkpoint control. It has been recently demonstrated that the loss of such functions in BRCA1-defective tumours results in a specific profile of sensitivity to anti-cancer drugs. Moreover, BRCA1 appears to retain a critical role in the response of cells to stress as well as to the growth promoting stimuli generated by estrogens and peptide growth factors. Therefore, it is conceivable that loss of a functional BRCA1 produces a general de-arrangement of cellular signaling which might allow the identification of specific and high priority targets and lead to individualized signal transduction-based anti-tumour approaches. We will review the most important findings related to BRCA1 effects on cellular signaling in order to depict a general scenario for selective chemopreventive and therapeutic strategies.
Export Options
About this article
Cite this article as:
Tagliaferri P., Tassone P., Pietragalla A., Rotundo S. M., Barbieri V., Budillon A., Caraglia M., Costanzo S. F. and Venuta S., Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours, Current Signal Transduction Therapy 2007; 2 (2) . https://dx.doi.org/10.2174/157436207780619491
DOI https://dx.doi.org/10.2174/157436207780619491 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide and Cancer Therapy: The Emperor has NO Clothes
Current Pharmaceutical Design Template Synthesis of Tubular Nanostructures for Loading Biologically Active Molecules
Current Topics in Medicinal Chemistry Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Molecular Docking and 3D-QSAR Studies on Quinolone-based HDAC Inhibitors
Letters in Drug Design & Discovery Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology Ribosome Display and Selection of Human Anti-Placental Growth Factor scFv Derived from Ovarian Cancer Patients
Protein & Peptide Letters Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery Nanoparticles, Promising Carriers in Drug Targeting: A Review
Current Drug Therapy The Role of Mass Spectrometry in the “Omics” Era
Current Organic Chemistry Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Design and Biological Evaluation of 3-Aryl-4-alkylpyrazol-5-amines Based on the Target Fishing
Current Computer-Aided Drug Design Synthesis of Coumarin linked Naphthalimide Conjugates as Potential Anticancer and Antimicrobial Agents
Letters in Drug Design & Discovery Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
Current Cancer Drug Targets Lanthanides as Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Endostatin: Preclinical Development as an Anticancer Agent
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine